PERSON DIRECTORY
Eric Schmidt
Eric Schmidt appears in 44 indexed conversations across Biotech Hangout, Moonshots, All-In. This directory brings every appearance, source, TL;DR, digest, and transcript into one searchable feed.
Episode 203 - November 13, 2026
Eric SchmidtYaron WerberPaul MatteisKate Haviland
XBI’s roughly 25% year-to-date gain masks a market still punishing binary risk and financing needs, favoring commercial businesses with pipeline upside.FDA confidence depends on predictable decisions and leadership continuity, while China’s stronger bargaining position has closed earlier licensing arbitrage.PepGen’s near-50% splicing improvement in DM1 is encouraging, but small numbers, potential renal toxicity and pivotal confirmation remain ahead.
Episode 200 - October 23, 2026
Daphne ZoharBrad LoncarChris GarabedianSam FazeliEric SchmidtJosh SchimmerMatt GlineAli Mortazavi
Moderna’s selloff puts a near-$100 billion valuation against $2.2–2.3 billion in annual revenue and established melanoma competition, though Loncar says the data strengthened the medical and commercial case.Tango’s PRMT5 inhibitor delivered an 82% response rate and 88% non-progression at nine months in heavily pretreated pancreatic cancer, but its shares fell; the MTAP-deleted opportunity may cover 30–40% of patients.
Episode 167 - December 19, 2025
Daphne ZoharBruce BoothEric Schmidt
Biotech’s year-end pause looks like healthy stock-picker consolidation, with XBI near 124 while mediocre data from Pyxis and Nektar were heavily punished.Nearly $9B of October-November follow-ons is creating indigestion, as first-day performance increasingly sets discounts for subsequent deals.Confidential S-1 flips could fuel a Q1 IPO rush, but recycled issuers and a disrupted FDA policy backdrop make quality and execution the key risks.


